CAS: 302964-02-9; 2-Boc-Aminothiazole-5-Carboxylic Acid

该化合物是一种受保护的氨基-硫氨酸衍生物,广泛用于有机合成和制药研究;三丁氧碳基(Boc)组在基本和核生殖条件下保持稳定,能够在多步骤合成途径中有选择地取消保护;二硝基苯核心为建造生物活性化合物提供了多功能的热循环脚手架,而碳本体酸功能允许通过恐吓或酯化进一步衍生.这种化合物由于与标准的混合试剂和正态保护群体战略相容,在丙二氧基-丁基碳基(Boc)组中具有特别宝贵的价值.其晶体性质有利于净化和定性,使它成为复杂的分子合成的实用中间体.

结构式图片

物理性质

MSDS等安全信息

欧盟法规

C&L通报

上下游产品

CAS号302964-01-8 2-((叔丁氧基羰基)氨基)噻... | CAS号745078-03-9 2-((叔丁氧基羰基)氨基)噻... | CAS号40283-46-3 2-氨基噻唑-5-甲酸 | CAS号24424-99-5 二碳酸二叔丁酯 | CAS号32955-21-8 2-氨基噻唑-5-羧酸酯 | CAS号731018-54-5 N-(5-氟-2-噻唑)-氨基...

合成工艺路线路线简述

    📜2-((叔丁氧基羰基)氨基)噻唑-5-羧酸甲酯置于水,Sodium Hydroxide,盐酸体系中,用 四氢呋喃,甲醇,水 用作溶剂,化学反应 16.0H,反应生成2-N-Boc-氨基噻唑-5-羧酸
    参考文献: Process For The Production Of 2-Amino-5-Fluorothiazole[fr] Procédé Pour L'Intermédiaire De Synthèse Du 2-Amino-5-Fluorothiazole
    标题: Process For The Production Of 2-Amino-5-Fluorothiazole[fr] Procédé Pour L'Intermédiaire De Synthèse Du 2-Amino-5-Fluorothiazole
    摘要:一种生产代表为化学式(i)的氟化合物或其盐的方法,其中r1和r2相同或不同,并且每个都选自包括氢原子,酰基,磺基和磷酰基的基团.

    海关参考信息

    专利信息


    专利号:WO-2011095125-A1
    优先权日:2010-02-02
    标 题:Synthesis methods and purification methods of dasatinib
    发明人：YAN RONG; YANG HAO; HOU WEN; XU YONGXIANG
    权利人:NAN JING CAVENDISH BIO ENGINEERING TECHNOLOGY CO LTD; YAN RONG; YANG HAO; HOU WEN; XU YONGXIANG
    摘要:Synthesis methods of dasatinib are provided, which comprise the following steps: reacting a compound of formula I with a compound of formula II to obtain a compound of formula III, and then connecting the compound of formula III with 2-chloro-6-methylaniline and 1-(2-hydroxyethyl)piperazine in any order to give dasatinib. Furthermore, purification methods of dasatinib are also provided.

    专利号:US-9108954-B2
    优先权日:2010-02-02
    标 题:Synthesis process of dasatinib and intermediate thereof
    发明人：YAN RONG; YANG HAO; HOU WEN; XU YONGXIANG
    权利人:YAN RONG; YANG HAO; HOU WEN; XU YONGXIANG; NAN JING CAVENDISH BIO ENGINEERING TECHNOLOGY CO LTD
    摘要:Synthesis process of dasatinib is disclosed, which includes the step of reacting the compound of formula I with that of formula II to obtain the compound of formula III. Also disclosed is the compound of formula III which is used as an intermediate for synthesizing dasatinib. The substituents of R1, R2, R3 or R4 in formulae I, II or III are defined as in the description.

    专利号:WO-2011095126-A1
    优先权日:2010-02-02
    标题:Synthesis process of dasatinib and intermediate thereof

    专利号:US-2013030177-A1
    优先权日:2010-02-02
    标题:Synthesis process of dasatinib and intermediate thereof

    专利号:EP-2532662-A1
    优先权日:2010-02-02
    标题 :Synthesis process of dasatinib and intermediate thereof

    专利号:EP-2532662-B1
    优先权日:2010-02-02
    标 题 :Synthesis process of dasatinib and intermediate thereof

    其他信息查阅

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    实用工具

    ⚠️全国化工行业净网倡议书
    📋制造商识别码
    📖 海关编码查询
    📝MSDS生成器

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知